Metastatic Melanoma: Key Trial Updates

Source: OncLive, September 2019


Sanjiv S. Agarwala, MD: Dirk, talking about the BRAF-positive population, the COLUMBUS trial was updated, you know, with the most recent BRAF/MEK combo. And Alex’s points are very interesting. That data were looking more impressive. Were you impressed with that? Is there something in that combination that’s different? What are your thoughts on that update?

Dirk Schadendorf, MD, PhD: I think the clinical efficacy data for encorafenib and binimetinib are very well in line with the other BRAF/MEK combinations. Third in market, I think there is absolutely no doubt that this combination is working. It’s clinically efficient and is working as good as what we have in hand.

Please consider helping a new melanoma project by completing the survey

Are you affected by melanoma? Have your say today by answering this online survey. It will take 5-8
minutes to complete. Be assured that all answers you provide will be kept strictly anonymous.

Audrey Rollin is a PhD candidate in Health Sciences from The University of Sydney. This research project
focuses on digital health for melanoma care in rural regions of Australia with a goal of understanding how
technology could help improving access to care and melanoma patients’ quality of life.

The ethical aspects of this study have been approved by the HREC of the University of Sydney 2018/903.
To complete the survey you have to meet the following requirements:
– cutaneous melanoma patient from stage 0 to IV,
– living in Australia, and
– over the age of 18.

https://redcap.sydney.edu.au/surveys/?s=XRLP4DJADY

Read the original full article